“Strike Early and Strike Strong”: Low LDL-Cholesterol and Low Albumin Predict Statin Hyporesponsiveness in Acute Coronary Syndrome
Open Access
- 18 March 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2312
Abstract
Background/Objectives: Many patients with acute coronary syndrome (ACS) fail to achieve adequate low-density lipoprotein-cholesterol (LDL-C) reduction, despite receiving high-intensity statin therapy. Identifying patients requiring early combination therapy remains a challenging task. This study aimed to determine the prevalence of statin hyporesponsiveness in patients with ACS and investigate the predictive role of baseline LDL-C and albumin levels. Methods: This retrospective study enrolled 366 patients with ACS treated with high-intensity statins (atorvastatin 40–80 mg). Hyporesponsiveness was defined as LDL-C reduction of p = 0.0002) and LDL-C (126.6 vs. 147.3 mg/dL, p < 0.0001) levels. Categorical analysis revealed that the combination of baseline LDL-C < 100 mg/dL and albumin < 40 g/L predicted hyporesponsiveness in 95.7% of cases. ROC curve analysis identified optimal predictive cut-offs of 128.50 mg/dL for LDL-C (area under the curve (AUC): 0.652) and 41.15 g/L for albumin (AUC: 0.618). The combined LDL-C + albumin model demonstrated superior predictive performance with an AUC of 0.670 (95% CI: 0.615–0.725). Conclusions: Low baseline LDL-C and low albumin are strong predictors of statin hyporesponsiveness in patients with ACS. These routinely obtained biomarkers can identify very high-risk patients who may benefit from proactive combination lipid-lowering therapy from hospital discharge, supporting the “strike early and strike strong” strategy and challenging the traditional stepwise approach.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023The Lancet, 2025
- Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART RegistryJACC, 2025
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary SyndromesJACC, 2025
- Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndromeJournal of Clinical Lipidology, 2024
- Cholesterol affects the relationship between albumin and major adverse cardiac events in patients with coronary artery disease: a secondary analysisScientific Reports, 2022
- Lipid paradox in patients with acute myocardial infarction: Potential impact of malnutritionClinical Nutrition, 2019
- Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C LoweringJAMA, 2018
- Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary SyndromeJACC, 2016
- Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin TherapyJACC, 2005
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004